Schrodinger reported robust software and drug discovery revenue in the second quarter. Lilly's planned multi-billion-dollar acquisition of Morphic also provides another validation point for ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Schrodinger, Inc. (SDGR) reports results for the quarter ended June 2025. While this widely-known consensus outlook is ...

Schrodinger, Inc. SDGR shares ended the last trading session 14.1% higher at $24.34. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Schrodinger, Inc. SDGR shares soared 27.4% in the last trading session to close at $24.49. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant Novartis that could generate $2.3 billion in milestone and royalty payments ...

Schrödinger is abandoning its CDC7 inhibitor after the therapy was linked to the deaths of two patients in a phase 1 leukemia trial. The biotech had been evaluating the asset, dubbed SGR-2921, in an ...